Medindia

X

Interpace Diagnostics to Present at 2017 BIO CEO & Investor Conference

Saturday, February 11, 2017 General News J E 4
Advertisement

PARSIPPANY, N.J., Feb. 10, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (IDXG) ("Interpace" or the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced that its President & Chief Executive Officer, Jack E. Stover, will deliver a corporate presentation at the 2017 BIO CEO & Investor Conference, being held February 13-14, 2017 at the Waldorf Astoria Hotel in New York. 

Details for this presentation are as follows:

  • 2017 BIO CEO & Investor Conference – webcast available
  • Time/Date: 4:30 pm ET on Monday, February 13, 2017
  • Location: Waldorf Astoria Hotel, New York              Presentation Room:  Conrad Room

A live webcast of Interpace Diagnostics' presentation may be accessed by logging onto the internet at http://www.veracast.com/webcasts/bio/ceoinvestor2017/69132493167.cfm. A replay will be archived and accessible for 90 days at the same website.

About Interpace Diagnostics Group

Interpace is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests: PancraGEN®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace's mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, please visit Interpace Diagnostics' website at www.interpacediagnostics.com.   

CONTACTS:Victor RobertsRedChip Companies407.644.4256, ext. 111victor@redchip.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/interpace-diagnostics-to-present-at-2017-bio-ceo--investor-conference-300405706.html

SOURCE Interpace Diagnostics Group, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Regulatory Update - Health Canada proposes stronge...
S
PA Physician General and Secretary of Aging Visit ...